Action - ISIS

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Premium

Dernier

57,56

Prix Achat

0,00

Prix Vente

0,00

Volume échangé

0,00 Fourchette du Jour 0,00

0,00 Plage de 52 semaines 0,00

Clôture Veille

57,56

Ouverture

Dernière Transaction

Dernière heure de transaction

Volume moyen (3 m)

Volume financier

VWAP

Isis Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference

CARLSBAD, Calif., Jan. 6 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (NASDAQ:ISIS), the leader in antisense therapeutics, today...

Excaliard Initiates Phase 2 Trials in U.S. for its Skin Scarring Drug, EXC 001

CARLSBAD, Calif., Jan. 5 /PRNewswire/ -- Excaliard Pharmaceuticals, Inc. announced today the initiation of three proof of concept Phase 2 trials...

Isis Pharmaceuticals to Receive $10 Million From OncoGenex' License of OGX-011 to Teva

OGX-011 Phase 3 Studies in First- and Second-Line Advanced Prostate Cancer and Non-Small Cell Lung Cancer Expected to Begin in 2010 and Early 2011...

Isis Pharmaceuticals (Nasdaq: ISIS) Letter to Shareholders

CARLSBAD, Calif., Nov. 23 /PRNewswire-FirstCall/ -- Dear Isis Supporters and Shareholders, I would like to start by thanking you for your...

Isis Pharmaceuticals to Present at the 4th Annual BIOCOM Investor Conference

CARLSBAD, Calif., Oct. 20 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (NASDAQ:ISIS), the leader in antisense therapeutics, today...

Isis Pharmaceuticals to Present at Morgan Stanley's Global Healthcare Unplugged Conference

CARLSBAD, Calif., Sept. 9 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (NASDAQ:ISIS), the leader in antisense therapeutics, today...

Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009

- Conference Call Webcast Thursday, August 6, 08:30 a.m. EDT at www.isispharm.com CARLSBAD, Calif., Aug. 6 /PRNewswire-FirstCall/ -- Isis...

Isis Pharmaceuticals to Present at Canaccord Adams' 29th Annual Global Growth Conference

CARLSBAD, Calif., Aug. 4 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (NASDAQ:ISIS), the leader in antisense therapeutics, today...

OncoGenex Appoints New CFO and Board Member

VANCOUVER, Feb. 14 /PRNewswire-FirstCall/ -- OncoGenex Technologies Inc., announced the appointment of Mr. Stephen Anderson as Chief Financial...

OncoGenex Announces Completion of $12.8 Million Venture Financing

VANCOUVER, Aug. 16 /PRNewswire-FirstCall/ -- OncoGenex Technologies Inc., a clinical-stage biotechnology company developing targeted...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

ISIS - Frequently Asked Questions (FAQ)

What is the current share price?

The current share price of is US$ 57,56

What is the 1 year trading range for share price?

has traded in the range of US$ 0,00 to US$ 0,00 during the past year

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
AAGRAfrican Agriculture Holdings Inc	US$ 0,1326 (0,00%)	0
AADRAdvisorShares Dorsey Wright ADR ETF	US$ 74,81 (0,00%)	0
AADIAadi Bioscience Inc	US$ 2,56 (0,00%)	0
AACGATA Creativity Global	US$ 0,8295 (0,00%)	0
AACBUArtius II Acquisition Inc	US$ 10,04 (0,00%)	0
AAGRAfrican Agriculture Holdings Inc	US$ 0,1326 (0,00%)	0
AADRAdvisorShares Dorsey Wright ADR ETF	US$ 74,81 (0,00%)	0
AADIAadi Bioscience Inc	US$ 2,56 (0,00%)	0
AACGATA Creativity Global	US$ 0,8295 (0,00%)	0
AACBUArtius II Acquisition Inc	US$ 10,04 (0,00%)	0
AAGRAfrican Agriculture Holdings Inc	US$ 0,1326 (0,00%)	0
AADRAdvisorShares Dorsey Wright ADR ETF	US$ 74,81 (0,00%)	0
AADIAadi Bioscience Inc	US$ 2,56 (0,00%)	0
AACGATA Creativity Global	US$ 0,8295 (0,00%)	0
AACBUArtius II Acquisition Inc	US$ 10,04 (0,00%)	0

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Ionis Pharmaceuticals, (ISIS)

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Statistiques et détails clés

ISIS Dernières nouvelles

Isis Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference

Excaliard Initiates Phase 2 Trials in U.S. for its Skin Scarring Drug, EXC 001

Isis Pharmaceuticals to Receive $10 Million From OncoGenex' License of OGX-011 to Teva

Isis Pharmaceuticals (Nasdaq: ISIS) Letter to Shareholders

Isis Pharmaceuticals to Present at the 4th Annual BIOCOM Investor Conference

Isis Pharmaceuticals to Present at Morgan Stanley's Global Healthcare Unplugged Conference

Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009

Isis Pharmaceuticals to Present at Canaccord Adams' 29th Annual Global Growth Conference

OncoGenex Appoints New CFO and Board Member

OncoGenex Announces Completion of $12.8 Million Venture Financing

ISIS - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Ionis Pharmaceuticals, (ISIS) Cours

Ionis Pharmaceuticals, (ISIS)

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Statistiques et détails clés

ISIS Dernières nouvelles

Isis Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference

Excaliard Initiates Phase 2 Trials in U.S. for its Skin Scarring Drug, EXC 001

Isis Pharmaceuticals to Receive $10 Million From OncoGenex' License of OGX-011 to Teva

Isis Pharmaceuticals (Nasdaq: ISIS) Letter to Shareholders

Isis Pharmaceuticals to Present at the 4th Annual BIOCOM Investor Conference

Isis Pharmaceuticals to Present at Morgan Stanley's Global Healthcare Unplugged Conference

Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009

Isis Pharmaceuticals to Present at Canaccord Adams' 29th Annual Global Growth Conference

OncoGenex Appoints New CFO and Board Member

OncoGenex Announces Completion of $12.8 Million Venture Financing

ISIS - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS